Johnson & Johnson Reports Strong One-Year Results for Shockwave Peripheral IVL in Complex Below-the-Knee PAD
Reuters
Nov 04
Johnson & Johnson Reports Strong One-Year Results for Shockwave Peripheral IVL in Complex Below-the-Knee PAD
Johnson & Johnson MedTech has announced the one-year results of the DISRUPT BTK II post-market study evaluating the safety and effectiveness of the Shockwave Peripheral Intravascular Lithotripsy (IVL) System for treating calcified lesions below the knee in patients with peripheral artery disease. The findings, which were presented at the Vascular InterVentional Advances (VIVA) 2025 meeting, included outcomes from 250 patients across 38 sites globally, with 80% having chronic limb-threatening ischemia (CLTI). At one year, 94.8% of patients were free from major target limb amputation, and 84.5% were free from clinically driven target revascularization. The results demonstrate the durability and safety profile of IVL in complex below-the-knee anatomies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.